This time last year, Cooley LLP wistfully remarked that M&A activity in the life sciences sector had decided to slim down and join the GLP-1 trend. Since then, dealmakers in the space have discovered their appetite again – and then some. With dealmakers chewing on US tariff-related uncertainties, US Food and Drug Administration leadership changes, shifting priorities at the US Department of Health and Human Services and an executive order on most-favored-nation pricing – the sector’s hunger for deals returned by mid-year, and life sciences M&A roared back with renewed confidence in transformative acquisitions. In this annual review that follows, Cooley LLP unpacks the latest trends and developments in the market and offers predictions for a robust life sciences M&A market.
Read the full article: 2026 Year Ahead for Life Sciences M&A: Competition and Creativity in a Dynamic Environment //
Source: https://www.lexology.com/library/detail.aspx?g=55547830-0e87-47da-9733-1ef232185b22